Diagnostic performance of a whole-body dynamic 68GA-DOTATOC PET/CT acquisition to differentiate physiological uptake of pancreatic uncinate process from pancreatic neuroendocrine tumor

被引:7
|
作者
Thuillier, Philippe [1 ,2 ]
Bourhis, David [2 ,3 ]
Karakatsanis, Nicolas [4 ]
Schick, Ulrike [5 ]
Metges, Jean Philippe [6 ]
Salaun, Pierre-Yves [2 ,3 ]
Kerlan, Veronique [1 ,2 ]
Abgral, Ronan [2 ,3 ]
机构
[1] Univ Hosp Brest, Dept Endocrinol, Blvd Tanguy Prigent, F-29609 Brest, France
[2] Univ Hosp Brest, EA GETBO 3878, Brest, France
[3] Univ Hosp Brest, Dept Nucl Med, Brest, France
[4] Cornell Univ, Weil Cornell Med Coll, Dept Radiol, Div Radiopharmaceut Sci, New York, NY 10021 USA
[5] Univ Hosp Brest, Dept Radiotherapy, Brest, France
[6] Univ Hosp Brest, Dept Oncol, Brest, France
关键词
Ga-68-DOTATOC PET; Ki; neuroendocrine tumor; pancreatic uncinate process; somatostatin receptor expression; SUVmax; DOTA-NOC; SOMATOSTATIN; GA-68-DOTATOC; QUANTIFICATION; PARAMETERS; RECEPTORS; IMAGE;
D O I
10.1097/MD.0000000000020021
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
To evaluate the diagnostic performance of net influx rate (Ki) values from a whole-body dynamic (WBD)Ga-68-DOTATOC-PET/CT acquisition to differentiate pancreatic neuroendocrine tumors (pNETs) from physiological uptake of pancreatic uncinate process (UP). Patients who were benefited from a WBD acquisition for the assessment of a known well-differentiated neuroendocrine tumor (NET)/suspicion of disease in the prospective GAPET-NET cohort were screened. Only patients with a confirmed pNET/UP as our gold standard were included. The positron emission tomography (PET) procedure consisted in a single-bed dynamic acquisition centered on the heart, followed by a whole-body dynamic acquisition and then a static acquisition. Dynamic (Ki calculated according to Patlak method), static (SUVmax, SUVmean, SUVpeak) parameters, and tumor-to-liver and tumor-to-spleen ratio (TLRKi and TSRKi (according to hepatic/splenic Ki)), tumor SUVmax to liver SUVmax (TM/LM), tumor SUVmax to liver SUVmean (TM/Lm), tumor SUVmax to spleen SUVmax (TM/SM), and tumor SUVmax to spleen SUVmean (TM/Sm) (according to hepatic/splenic SUVmax and SUVmean respectively) were calculated. A Receiver Operating Characteristic (ROC) analysis was performed to evaluate their diagnostic performance to distinguish UP from pNET. One hundred five patients benefited from a WBD between July 2018 and July 2019. Eighteen (17.1%) had an UP and 26 (24.8%) a pNET. For parameters alone, the Ki and SUVpeak had the best sensitivity (88.5%) while the Ki, SUVmax, and SUVmean had the best specificity (94.4%). The best diagnostic accuracy was obtained with Ki (90.9%). For ratios, the TLRKi and the TSRKi had the best sensitivity (95.7%) while the TM/SM and TM/Sm the best specificity (100%). TLRKi had the best diagnostic accuracy (95.1%) and the best area under the curve (AUC) (0.990). Our study is the first one to evaluate the interest of a WBD acquisition to differentiate UP from pNETs and shows excellent diagnostic performances of the Ki approach.
引用
收藏
页数:7
相关论文
共 50 条
  • [21] 68Ga-DOTATOC PET/CT in Pancreatic Metastasis From Clear Cell Renal Cell Carcinoma
    Mansour, Nabeel
    Rangan, Kasturi
    Tiling, Reinhold
    Ruebenthaler, Johannes
    Fabritius, Matthias P.
    CLINICAL NUCLEAR MEDICINE, 2023, 48 (08) : 712 - 713
  • [22] Pancreatic metastases from primary ileal NET only detected by 68Ga-DOTATOC PET/CT
    P. Mapelli
    F. Fallanca
    A. Franchini
    L. Albarello
    E. G. Vanoli
    S. Partelli
    F. Muffatti
    L. Gianolli
    M. Falconi
    M. Picchio
    European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47 : 2713 - 2714
  • [23] Staging of neuroendocrine tumours: comparison of [68Ga]DOTATOC multiphase PET/CT and whole-body MRI
    Schraml, C.
    Schwenzer, N. F.
    Sperling, O.
    Aschoff, P.
    Lichy, M. P.
    Mueller, M.
    Brendle, C.
    Werner, M. K.
    Claussen, C. D.
    Pfannenberg, C.
    CANCER IMAGING, 2013, 13 (01): : 63 - 72
  • [24] Risk stratification in pancreatic neuroendocrine tumours: the role of combined 68Ga-DOTATOC and 18F-FDG PET/CT
    Mapelli, Paola
    Partelli, Stefano
    Salgarello, Matteo
    Muffatti, Francesca
    Rancoita, Paola Maria
    Pasetto, Stefano
    Gianolli, Luigi
    Falconi, Massimo
    Picchio, Maria
    JOURNAL OF NUCLEAR MEDICINE, 2018, 59
  • [25] Dual tracer 68Ga-DOTATOC and 18F-FDG PET/CT for risk stratification in pancreatic neuroendocrine neoplasms
    Mapelli, P.
    Salgarello, M.
    Partelli, S.
    Muffatti, F.
    Pasetto, S.
    Rancoita, P.
    Gianolli, L.
    Falconi, M.
    Picchio, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S64 - S65
  • [26] A case of positive 68Ga-DOTATOC-PET/CT pancreatic heterotopia mimicking an intestinal neuroendocrine tumor
    Zilli, Alessandra
    Fanetti, Ilaria
    Conte, Dario
    Massironi, Sara
    CLINICAL IMAGING, 2018, 49 : 156 - 158
  • [27] Spleen Scan for 68Ga-DOTATOC PET-Positive Pancreatic Tail Lesion: Differential Diagnosis of Neuroendocrine Tumor from Accessory Spleen
    Hyun Gee Ryoo
    Hongyoon Choi
    Gi Jeong Cheon
    Nuclear Medicine and Molecular Imaging, 2020, 54 : 43 - 47
  • [28] Spleen Scan for 68Ga-DOTATOC PET-Positive Pancreatic Tail Lesion: Differential Diagnosis of Neuroendocrine Tumor from Accessory Spleen
    Ryoo, Hyun Gee
    Choi, Hongyoon
    Cheon, Gi Jeong
    NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 54 (01) : 43 - 47
  • [29] Population-based input function (PBIF) applied to dynamic whole-body 68Ga-DOTATOC-PET/CT acquisition
    Thuillier, Philippe
    Bourhis, David
    Pavoine, Mathieu
    Metges, Jean-Philippe
    Le Pennec, Romain
    Schick, Ulrike
    Blanc-Beguin, Frederique
    Hennebicq, Simon
    Salaun, Pierre-Yves
    Kerlan, Veronique
    Karakatsanis, Nicolas A.
    Abgral, Ronan
    FRONTIERS IN NUCLEAR MEDICINE, 2022, 2
  • [30] Prognostic value of functional tumor burden on 68Ga-DOTATOC PET/CT in patients with pancreatic neuro-endocrine tumors
    Ohnona, J.
    Nataf, V
    Gauthe, M.
    Balogova, S.
    Benesty, O. Belissant
    Zhang-Yin, J.
    Talbot, J-N
    Montravers, F.
    NEOPLASMA, 2019, 66 (01) : 140 - 148